149 related articles for article (PubMed ID: 36337926)
1. Plasminogen Activator Inhibitor-1-Positive Platelet-Derived Extracellular Vesicles Predicts MACE and the Proinflammatory SMC Phenotype.
Jung RG; Duchez AC; Simard T; Dhaliwal S; Gillmore T; Di Santo P; Labinaz A; Ramirez FD; Rasheed A; Robichaud S; Ouimet M; Short S; Clifford C; Xiao F; Lordkipanidzé M; Burger D; Gadde S; Rayner KJ; Hibbert B
JACC Basic Transl Sci; 2022 Oct; 7(10):985-997. PubMed ID: 36337926
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of plasminogen activator inhibitor-1 as a biomarker of unplanned revascularization and major adverse cardiac events in coronary angiography and percutaneous coronary intervention.
Jung RG; Simard T; Di Santo P; Dhaliwal S; Sypkes C; Duchez AC; Moreland R; Taylor K; Parlow S; Visintini S; Labinaz A; Marbach J; Sarathy K; Bernick J; Joseph J; Boland P; Abdel-Razek O; Harnett DT; Ramirez FD; Hibbert B
Thromb Res; 2020 Jul; 191():125-133. PubMed ID: 32447094
[TBL] [Abstract][Full Text] [Related]
3. Role of plasminogen activator inhibitor-1 in coronary pathophysiology.
Jung RG; Simard T; Labinaz A; Ramirez FD; Di Santo P; Motazedian P; Rochman R; Gaudet C; Faraz MA; Beanlands RSB; Hibbert B
Thromb Res; 2018 Apr; 164():54-62. PubMed ID: 29494856
[TBL] [Abstract][Full Text] [Related]
4. Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study.
Mehran R; Baber U; Steg PG; Ariti C; Weisz G; Witzenbichler B; Henry TD; Kini AS; Stuckey T; Cohen DJ; Berger PB; Iakovou I; Dangas G; Waksman R; Antoniucci D; Sartori S; Krucoff MW; Hermiller JB; Shawl F; Gibson CM; Chieffo A; Alu M; Moliterno DJ; Colombo A; Pocock S
Lancet; 2013 Nov; 382(9906):1714-22. PubMed ID: 24004642
[TBL] [Abstract][Full Text] [Related]
5. Plasma and platelet plasminogen activator inhibitor-1 in patients with acute myocardial infarction.
Soeki T; Tamura Y; Fukuda N; Ito S
Jpn Circ J; 2000 Aug; 64(8):547-53. PubMed ID: 10952148
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological Targeting of Plasminogen Activator Inhibitor-1 Decreases Vascular Smooth Muscle Cell Migration and Neointima Formation.
Ji Y; Weng Z; Fish P; Goyal N; Luo M; Myears SP; Strawn TL; Chandrasekar B; Wu J; Fay WP
Arterioscler Thromb Vasc Biol; 2016 Nov; 36(11):2167-2175. PubMed ID: 27659097
[TBL] [Abstract][Full Text] [Related]
7. Platelet-derived growth factor and transforming growth factor-beta regulate plasminogen activator inhibitor-1 synthesis in vascular smooth muscle cells.
Reilly CF; McFall RC
J Biol Chem; 1991 May; 266(15):9419-27. PubMed ID: 2033043
[TBL] [Abstract][Full Text] [Related]
8. Independent Predictors of Major Adverse Events following Coronary Stenting over 28 Months of Follow-Up.
Golukhova EZ; Grigorian MV; Ryabinina MN; Bulaeva NI; Fortmann S; Serebruany VL
Cardiology; 2015; 132(3):176-81. PubMed ID: 26277984
[TBL] [Abstract][Full Text] [Related]
9. The inflammatory cytokine oncostatin M induces PAI-1 in human vascular smooth muscle cells in vitro via PI 3-kinase and ERK1/2-dependent pathways.
Demyanets S; Kaun C; Rychli K; Rega G; Pfaffenberger S; Afonyushkin T; Bochkov VN; Maurer G; Huber K; Wojta J
Am J Physiol Heart Circ Physiol; 2007 Sep; 293(3):H1962-8. PubMed ID: 17604327
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of short-term (1 to 3 months) dual antiplatelet therapy in patients undergoing percutaneous coronary interventions: a meta-analysis of randomized controlled trials.
Kheiri B; Simpson TF; Osman M; Golwala H; Radaideh Q; Kumar K; Rahmouni H; Divanji P; Cigarroa JE; Zahr F
J Thromb Thrombolysis; 2020 Nov; 50(4):867-873. PubMed ID: 32607653
[TBL] [Abstract][Full Text] [Related]
11. Dual Antiplatelet Therapy Discontinuation, Platelet Reactivity, and Adverse Outcomes After Successful Percutaneous Coronary Intervention.
Redfors B; Kirtane AJ; Liu M; Musikantow DR; Witzenbichler B; Rinaldi MJ; Metzger DC; Weisz G; Stuckey TD; Brodie BR; Ben-Yehuda O; Mehran R; Stone GW
JACC Cardiovasc Interv; 2022 Apr; 15(8):797-806. PubMed ID: 35450679
[TBL] [Abstract][Full Text] [Related]
12. [Meta-analysis on safety and efficacy of dual antiplatelet therapy combining with proton pump inhibitors for patients after percutaneous coronary intervention].
Che QQ; Wu Q; Liang YB; Sun RM; Lyu QW; Ma JL; Hu H; Lin X; Xu GL; Sun SG; Zhang C; Wang QY; Yu J; Bai F
Zhonghua Xin Xue Guan Bing Za Zhi; 2019 Feb; 47(2):129-140. PubMed ID: 30818941
[No Abstract] [Full Text] [Related]
13. How Do Lipoprotein(a) Concentrations Affect Clinical Outcomes for Patients With Stable Coronary Artery Disease Who Underwent Different Dual Antiplatelet Therapy After Percutaneous Coronary Intervention?
Cui K; Yin D; Zhu C; Song W; Wang H; Jia L; Zhang R; Wang H; Cai Z; Feng L; Dou K
J Am Heart Assoc; 2022 May; 11(9):e023578. PubMed ID: 35475627
[TBL] [Abstract][Full Text] [Related]
14. Association between plasminogen activator inhibitor-1 and cardiovascular events: a systematic review and meta-analysis.
Jung RG; Motazedian P; Ramirez FD; Simard T; Di Santo P; Visintini S; Faraz MA; Labinaz A; Jung Y; Hibbert B
Thromb J; 2018; 16():12. PubMed ID: 29991926
[TBL] [Abstract][Full Text] [Related]
15. Biomarkers of platelet activation and cardiovascular risk in the DAPT trial.
Berg DD; Yeh RW; Mauri L; Morrow DA; Kereiakes DJ; Cutlip DE; Gao Q; Jarolim P; Michelson AD; Frelinger AL; Cange AL; Sabatine MS; O'Donoghue ML
J Thromb Thrombolysis; 2021 Apr; 51(3):675-681. PubMed ID: 32683645
[TBL] [Abstract][Full Text] [Related]
16. Expression of the plasminogen activator system in the human vascular wall.
Salame MY; Samani NJ; Masood I; deBono DP
Atherosclerosis; 2000 Sep; 152(1):19-28. PubMed ID: 10996335
[TBL] [Abstract][Full Text] [Related]
17. Influence of Baseline Anemia on Dual Antiplatelet Therapy Cessation and Risk of Adverse Events After Percutaneous Coronary Intervention.
Faggioni M; Baber U; Sartori S; Chandrasekhar J; Cohen DJ; Henry TD; Claessen BE; Dangas GD; Gibson CM; Krucoff MW; Vogel B; Moliterno DJ; Sorrentino S; Colombo A; Chieffo A; Kini A; Farhan S; Ariti C; Witzenbichler B; Weisz G; Steg PG; Pocock S; Mehran R
Circ Cardiovasc Interv; 2019 Apr; 12(4):e007133. PubMed ID: 30998384
[TBL] [Abstract][Full Text] [Related]
18. Benefit and Risk of Prolonged Dual Antiplatelet Therapy After Percutaneous Coronary Intervention With Drug-Eluting Stents in Patients With Elevated Lipoprotein(a) Concentrations.
Cui K; Wang HY; Yin D; Zhu C; Song W; Wang H; Jia L; Zhang D; Song C; Feng L; Dou K
Front Cardiovasc Med; 2021; 8():807925. PubMed ID: 34988134
[No Abstract] [Full Text] [Related]
19. Thrombin stimulates expression of tissue-type plasminogen activator and plasminogen activator inhibitor type 1 in cultured human vascular smooth muscle cells.
Wojta J; Gallicchio M; Zoellner H; Hufnagl P; Last K; Filonzi EL; Binder BR; Hamilton JA; McGrath K
Thromb Haemost; 1993 Sep; 70(3):469-74. PubMed ID: 8259551
[TBL] [Abstract][Full Text] [Related]
20. Real-World Dual Antiplatelet Therapy Following Polymer-Free Sirolimus-Eluting Stent Implantations to Treat Coronary Artery Disease.
Krackhardt F; Waliszewski M; Kočka V; Toušek P; Janek B; Hudec M; Lozano F; Roman KG; Del Blanco BG; Mauri J; Heang TM; Ahn TH; Jeong MH; Herberger D; Tomulic V; Levy G; Sebagh L; Rischner J; Pansieri M
Cardiovasc Drugs Ther; 2020 Jun; 34(3):335-344. PubMed ID: 32212061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
